![]()
|
|
|
‘Twas the year of the M&A boom …
December 2009
SHARING OPTIONS:
‘Twas
the end of 2009, and in the ddn newsroom,
the
editors and writers gathered to reflect on Big Pharma’s M&A boom.
In a
rare moment of quiet, away from their desks, visions
of dollar signs loomed large and grotesque.
News
of layoffs and job cuts rang in their ears, but
Big Pharma’s buyouts somehow overcame most analysts’ fears. “The
economy tanked, but Big Pharma prevailed,” said Amy Swinderman, sipping her
Malbec.
“This year was a blur,” she sighed, “and my desk is a wreck!” “Pfizer/Wyeth,
Merck/Schering, Roche/Genentech, Gilead/CV Therapeutics,” mused Jeff Bouley,
swirling the scotch in his crystal.
“Billions
of dollars spent; lots of midnight deadlines,” he recalled, seeming almost
wistful.
“Plenty of multimillion dollar deals, too,” Dave Hutton chimed in. Clad in his new LeBron James jersey, the names “J&J” and “BMS” gave him a grin. Cracking
open his Diet Pepsi, Dave added, “I also put Phase Forward on speed dial. Yet
the news wasn’t all good; I also covered many a failed drug trial.” “I
had beaucoup rendez-vous with sanofi-aventis,” added Lori Lesko, her keyboard
littered with cookie.
“Laboratorios
Kendrick, Medley, BiPar Sciences, Shantha, Fovea … to many an acquisition, the
French pharma said, ‘oui.’”
“I’ve
enjoyed this brief respite; it’s really been fun,” interrupted Lloyd Dunlap,
wrapping gifts in red and green tissue.
“But
Qiagen just bought SA Biosciences for $90 mil, so we’d better move on to our
January issue!”
So from
all of us at ddn—Amy, Jeff, Dave, Lloyd
and Lori—
We
wish you an even more successful 2010, and we look forward to telling your
story. Back |
|
||
|
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|